Skip to Main Content

Paper Details

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.
Blood Adv
5
2022
AML, BCL2, CD14, CD14+, DORA, MAPK14, VEN, acute myeloid leukemia, doramapimod, leukemic, monocytes, monocytic, monocytic and undifferentiated leukemias, p38 MAPK, patient, primary stromal cells, progenitor, tumor, tumor cell, venetoclax
Cell Differentiation, Humans, Immunophenotyping, Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2, p38 Mitogen-Activated Protein Kinases
Author NameAffiliation
Stephen E Kurtz
Stephen E Kurtz
Christopher A Eide
Andy Kaempf
Nicola Long
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University
Olga Nikolova
Brian J Druker
Brian J Druker
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Knight Cancer Institute, Oregon Health & Science University
Bill H ChangKnight Cancer Institute, Doernbecher Children's Hospital, Oregon Health & Science University
Jeffrey W Tyner
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University
Anupriya Agarwal
Anupriya Agarwal
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University
  • 1 - 16

Datasets

Release 1.2